GlassScriptPhysician profile
Graceanna Baker
NPI 1174166169
$2,171.93
in general payments reported to CMS, 2019-2025
11 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.22 · 2022: $1,193 · 2023: $356 · 2024: $178 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $964.61 | 2022 | |
| Merck Sharp & Dohme LLC | $413.48 | 2022-2025 | Keytruda, Lenvima, Keytruda Qlex |
| Eisai INC. | $235.14 | 2022-2025 | |
| Genmab U.S., INC. | $167.70 | 2024-2025 | Tivdak |
| Baxter Healthcare | $116.41 | 2023-2024 | Adept, Perclot |
| Myriad Genetic Laboratories, INC. | $93.56 | 2022 | |
| Glaxosmithkline, LLC. | $58.62 | 2023-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $53.17 | 2023-2024 | Lynparza |
| Spr Therapeutics, INC | $25.22 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.14 | 2023 | Libtayo |
| Caris Mpi, INC. | $21.88 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Graceanna Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.